Obsidian Therapeutics Inc.(OBX)

Biotechnology · Cambridge, MA

$13.47-0.38 (-2.71%)

Delayed quote: Oct 6, 2026, 2:19 PM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T18:22:24.022Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:22:24.022Z.

Quote observation: 2026-10-06T18:19:55.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 14,005,216
Total debt: N/A
Cash: N/A
TTM revenue: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

OBX EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

OBX Competitors' EV/Sales Ratio

OBX

Obsidian Therapeutics Inc.

Current

Market Cap

$14.01M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HIND

Vyome Holdings, Inc.

vs OBX

Market Cap

$13.93M

EV/Sales Ratio

46.73x

TTM Avg

16.53x

3Y Avg

4.93x

5Y Avg

3.45x

SINT

Sintx Technologies, Inc.

vs OBX

Market Cap

$13.78M

EV/Sales Ratio

9.59x

TTM Avg

6.53x

3Y Avg

5.18x

5Y Avg

1267.27x

PLSM

Pulsenmore Ltd. Ordinary Shares

vs OBX

Market Cap

$14.44M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OPTH

Optimi Health Corp.

vs OBX

Market Cap

$13.48M

EV/Sales Ratio

63.56x

TTM Avg

135.82x

3Y Avg

650.44x

5Y Avg

556.96x

PASG

Passage Bio, Inc.

vs OBX

Market Cap

$13.40M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INAB

IN8bio, Inc.

vs OBX

Market Cap

$13.33M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs OBX

Market Cap

$13.33M

EV/Sales Ratio

0.49x

TTM Avg

1.89x

3Y Avg

1.89x

5Y Avg

1.89x

KTTA

Pasithea Therapeutics Corp.

vs OBX

Market Cap

$14.92M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ZJYL

Jin Medical International Ltd.

vs OBX

Market Cap

$15.11M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Obsidian Therapeutics Inc. (OBX)	$14.01M	N/A	N/A	N/A	N/A
Vyome Holdings, Inc. (HIND)vs ›	$13.93M	46.73x	16.53x	4.93x	3.45x
Sintx Technologies, Inc. (SINT)vs ›	$13.78M	9.59x	6.53x	5.18x	1267.27x
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.44M	N/A	N/A	N/A	N/A
Optimi Health Corp. (OPTH)vs ›	$13.48M	63.56x	135.82x	650.44x	556.96x
Passage Bio, Inc. (PASG)vs ›	$13.40M	N/A	N/A	N/A	N/A
IN8bio, Inc. (INAB)vs ›	$13.33M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$13.33M	0.49x	1.89x	1.89x	1.89x
Pasithea Therapeutics Corp. (KTTA)vs ›	$14.92M	N/A	N/A	N/A	N/A
Jin Medical International Ltd. (ZJYL)vs ›	$15.11M	N/A	N/A	N/A	N/A

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics